Design of experiments approach on the compaction properties of co-amorphous tablets

References

• Agrawal A, Dudhedia M, Deng W, Shepard K, Zhong L, Povilaitis E, Zimny E. 2016. Development of tablet formulation of amorphous solid dispersions prepared by hot melt extrusion using quality by design approach. AAPS PharmSciTech. 17(1):214–232. doi: 10.1208/s12249-015-0472-0.
   PubMed Web of Science ®Google Scholar
• Ayenew Z, Paudel A, Rombaut P, Van Den Mooter G. 2012. Effect of compression on non-isothermal crystallization behaviour of amorphous indomethacin. Pharm Res. 29(9):2489–2498. doi: 10.1007/s11095-012-0778-5.
   PubMed Web of Science ®Google Scholar
• Baghel S, Cathcart H, O'Reilly NJ. 2016. Polymeric amorphous solid dispersions: a review of amorphization, crystallization, stabilization, solid-state characterization, and aqueous solubilization of biopharmaceutical classification system class II drugs. J Pharm Sci. 105(9):2527–2544. doi: 10.1016/j.xphs.2015.10.008.
   PubMed Web of Science ®Google Scholar
• Be̅rziņš K, Suryanarayanan R. 2018. Compression-induced crystallization in sucrose-polyvinylpyrrolidone amorphous solid dispersions. Cryst Growth Des. 18(2):839–848. doi: 10.1021/acs.cgd.7b01305.
   Web of Science ®Google Scholar
• Bhujbal SV, Mitra B, Jain U, Gong Y, Agrawal A, Karki S, Taylor LS, Kumar S, Zhou Q. 2021. Pharmaceutical amorphous solid dispersion: a review of manufacturing strategies. Acta Pharm Sin B. 11(8):2505–2536. doi: 10.1016/j.apsb.2021.05.014.
   PubMed Web of Science ®Google Scholar
• da Costa NF, Daniels R, Fernandes AI, Pinto JF. 2022. Downstream processing of amorphous and co-amorphous olanzapine powder blends. Pharmaceutics. 14(8):1535. doi: 10.3390/pharmaceutics14081535.
   PubMed Web of Science ®Google Scholar
• Darji MA, Lalge RM, Marathe SP, Mulay TD, Fatima T, Alshammari A, Lee HK, Repka MA, Narasimha Murthy S. 2018. Excipient stability in oral solid dosage forms: a review. AAPS PharmSciTech. 19(1):12–26. doi: 10.1208/s12249-017-0864-4.
   PubMed Web of Science ®Google Scholar
• Démuth B, Nagy ZK, Balogh A, Vigh T, Marosi G, Verreck G, Van Assche I, Brewster ME. 2015. Downstream processing of polymer-based amorphous solid dispersions to generate tablet formulations. Int J Pharm. 486(1-2):268–286. doi: 10.1016/j.ijpharm.2015.03.053.
   PubMedGoogle Scholar
• Dengale SJ, Grohganz H, Rades T, Löbmann K. 2016. Recent advances in co-amorphous drug formulations. Adv Drug Deliv Rev. 100:116–125. doi: 10.1016/j.addr.2015.12.009.
   PubMed Web of Science ®Google Scholar
• Eriksson L, Johansson E, Kettaneh-Wold N, Wikström C, Wold S. 2008. Design of experiments: principles and applications. 3rd ed. Umeå: Umetrics.
   Google Scholar
• Fell JT, Newton JM. 1970. Determination of tablet strength by the diametral-compression test. J Pharm Sci. 59(5):688–691. doi: 10.1002/jps.2600590523.
   PubMed Web of Science ®Google Scholar
• Grohganz H, Löbmann K, Priemel P, Tarp Jensen K, Graeser K, Strachan C, Rades T. 2013. Amorphous drugs and dosage forms. J Drug Delivery Sci Technol. 23(4):403–408. doi: 10.1016/S1773-2247(13)50057-8.
   Web of Science ®Google Scholar
• Hentzschel CM, Sakmann A, Leopold CS. 2012. Comparison of traditional and novel tableting excipients: physical and compaction properties. Pharm Dev Technol. 17(6):649–653. doi: 10.3109/10837450.2011.572897.
   PubMed Web of Science ®Google Scholar
• Laitinen R, Löbmann K, Strachan CJ, Grohganz H, Rades T. 2013. Emerging trends in the stabilization of amorphous drugs. Int J Pharm. 453(1):65–79. doi: 10.1016/j.ijpharm.2012.04.066.
   PubMed Web of Science ®Google Scholar
• Lenz E, Jensen KT, Blaabjerg LI, Knop K, Grohganz H, Lobmann K, Rades T, Kleinebudde P. 2015. Solid-state properties and dissolution behaviour of tablets containing co-amorphous indomethacin-arginine. Eur J Pharm Biopharm. 96:44–52. doi: 10.1016/j.ejpb.2015.07.011.
   PubMed Web of Science ®Google Scholar
• Liu J, Grohganz H, Löbmann K, Rades T, Hempel NJ. 2021. Co-amorphous drug formulations in numbers: recent advances in co-amorphous drug formulations with focus on co-formability, molar ratio, preparation methods, physical stability, in vitro and in vivo performance, and new formulation strategies. Pharmaceutics. 13(3):389. doi: 10.3390/pharmaceutics13030389.
   PubMed Web of Science ®Google Scholar
• Liu J, Rades T, Grohganz H. 2020. Determination of the optimal molar ratio in amino acid-based coamorphous systems. Mol Pharm. 17(4):1335–1342. doi: 10.1021/acs.molpharmaceut.0c00042.
   PubMedGoogle Scholar
• Lobmann K, Grohganz H, Laitinen R, Strachan C, Rades T. 2013. Amino acids as co-amorphous stabilizers for poorly water soluble drugs–Part 1: preparation, stability and dissolution enhancement. Eur J Pharm Biopharm. 85(3 Pt B):873–881. doi: 10.1016/j.ejpb.2013.03.014.
   PubMed Web of Science ®Google Scholar
• Ma X, Ellenberger D, O’Donnell KP, Williams RO. 2022. Optimizing the formulation of poorly water-soluble drugs. In: Williams RO, Watts AB, Miller DA, editors. Formulating poorly water soluble drugs. 3rd ed. Cham: Springer. p. 33–102.
   Google Scholar
• Meynard J, Amado-Becker F, Tchoreloff P, Mazel V. 2022. On the complexity of predicting tablet capping. Int J Pharm. 623:121949. doi: 10.1016/j.ijpharm.2022.121949.
   PubMedGoogle Scholar
• Ojarinta R, Saarinen J, Strachan CJ, Korhonen O, Laitinen R. 2018. Preparation and characterization of multi-component tablets containing co-amorphous salts: combining multimodal non-linear optical imaging with established analytical methods. Eur J Pharm Biopharm. 132:112–126. doi: 10.1016/j.ejpb.2018.09.013.
   PubMed Web of Science ®Google Scholar
• Patel S, Kou X, Hou H, Huang Y, Strong JC, Zhang GGZ, Sun CC. 2017. Mechanical properties and tableting behavior of amorphous solid dispersions. J Pharm Sci. 106(1):217–223. doi: 10.1016/j.xphs.2016.08.021.
   PubMed Web of Science ®Google Scholar
• Picker KM. 2001. Time dependence of elastic recovery for characterization of tableting materials. Pharm Dev Technol. 6(1):61–70. doi: 10.1081/pdt-100000014.
   PubMed Web of Science ®Google Scholar
• Pitt KG, Heasley MG. 2013. Determination of the tensile strength of elongated tablets. Powder Technol. 238:169–175. doi: 10.1016/j.powtec.2011.12.060.
   Web of Science ®Google Scholar
• Quodbach J, Kleinebudde P. 2015. Performance of tablet disintegrants: impact of storage conditions and relative tablet density. Pharm Dev Technol. 20(6):762–768. doi: 10.3109/10837450.2014.920357.
   PubMed Web of Science ®Google Scholar
• Quodbach J, Kleinebudde P. 2016. A critical review on tablet disintegration. Pharm Dev Technol. 21(6):763–774.
   PubMed Web of Science ®Google Scholar
• Shi Q, Wang Y, Moinuddin SM, Feng X, Ahsan F. 2022. Co-amorphous drug delivery systems: a review of physical stability, in vitro and in vivo performance. AAPS PharmSciTech. 23(7):259. doi: 10.1208/s12249-022-02421-7.
   PubMed Web of Science ®Google Scholar
• Sørensen C-M, Rantanen J, Grohganz H. 2023. Compaction behavior of co-amorphous systems. Pharmaceutics. 15(3):858. doi: 10.3390/pharmaceutics15030858.
   PubMed Web of Science ®Google Scholar
• Thakral NK, Mohapatra S, Stephenson GA, Suryanarayanan R. 2015. Compression-induced crystallization of amorphous indomethacin in tablets: characterization of spatial heterogeneity by two-dimensional X-ray diffractometry. Mol Pharm. 12(1):253–263. doi: 10.1021/mp5005788.
   PubMedGoogle Scholar
• Triboandas H, Pitt K, Bezerra M, Ach-Hubert D, Schlindwein W. 2022. Itraconazole amorphous solid dispersion tablets: formulation and compaction process optimization using quality by design principles and tools. Pharmaceutics. 14(11):2398. doi: 10.3390/pharmaceutics14112398.
   PubMed Web of Science ®Google Scholar
• Van den Mooter G. 2012. The use of amorphous solid dispersions: a formulation strategy to overcome poor solubility and dissolution rate. Drug Disc Today. 9(2):e79–e85. doi: 10.1016/j.ddtec.2011.10.002.
   Google Scholar